Ardisia crispa roots inhibit cyclooxygenase and suppress angiogenesis

BMC Complementary and Alternative Medicine

Looi Ting Yeong³  Che Norma Mat Taib¹  Latifah Saiful Yazan³  Roslida Abdul Hamid³  Dayang Erna Zulaikha Awang Hamsin² 

[1] Department of Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor;Department of Paraclinical Science, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kuching 93150, Sarawak;Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor

关键词: Soy lipoxygenase assay;    LOX inhibitor;    COX inhibitor;    Ardisia crispa;   

Others  :  1220221
DOI  :  10.1186/1472-6882-14-102

 received in 2013-07-22, accepted in 2014-03-14,  发布年份 2014

【 摘 要 】

Background

In our previous studies conducted on Ardisia crispa roots, it was shown that Ardisia crispa root inhibited inflammation-induced angiogenesis in vivo. The present study was conducted to identify whether the anti-angiogenic properties of Ardisia crispa roots was partly due to either cyclooxygenase (COX) or/and lipoxygenase (LOX) activity inhibition in separate in vitro studies.

Methods

Benzoquinonoid fraction (BQ) was isolated from hexane extract by column chromatography, and later analyzed by using gas chromatography–mass spectrometry (GC-MS). Anti-angiogenic effect was studied on mouse sponge implantation assay. Ardisia crispa ethanolic rich fraction (ACRH), quinone-rich fraction (QRF) and BQ were screened for COX assay to evaluate their selectivity towards two isoforms (COX-1 and COX-2), The experiment on soy lipoxygenase (LOX) inhibitory assay was also performed to determine the inhibitory effect of ACRH, QRF and BQ on soy LOX.

Results

BQ was confirmed to consist of 2-methoxy-6-undecyl-1,4-benzoquinone, when compared with previous data. Antiangiogenesis study exhibited a reduction of mean vascular density (MVD) in both ACRH and QRF, compared to control. In vitro study showed that both ACRH and QRF inhibited both COX-1 and COX-2, despite COX-2 inhibition being slightly higher than COX-1 in BQ. On the other hand, both ACRH and QRF were shown to have poor LOX inhibitory activity, but not BQ.

Conclusions

In conclusion, ACRH and QRF might possibly exhibit its anti-angiogenic effect by inhibiting cyclooxygenase. However, both of them were shown to possess poor LOX inhibitory activity. On the other hand, BQ displayed selectivity to COX-2 inhibitory property as well as LOX inhibitory effect.

【 授权许可】

   
2014 Awang Hamsin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Liekens S, De Clercq E, Neyts J: Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001, 61:253-270.
• [2]Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
• [3]Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285:1182-1186.
• [4]Dubois RN, Abramsom SB, Crofford L, Gupta RA, Simon LS, Van De Putte LBA, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998, 12(12):1063-1073.
• [5]Crofford LJ: Rational Use of analgesic and antiinflammatory drugs. N Engl J Med 2001, 345:1844-1846.
• [6]Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC: Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002, 55:429-434.
• [7]Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79:185-188.
• [8]Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
• [9]Steinhilber D: 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 1999, 6:71-85.
• [10]Romano M, Catalano A, Nutini M, D’Urbano E, Crescenzi C, Claria J, Libner R, Davi G, Procopio A: 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J 2001, 15:2326-2336.
• [11]Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM: The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 2003, 100(17):9968-9973.
• [12]Kang YH, Kim WH, Park MK, Han BH: Antimetastatic and antitumor effects of benzoquinonoid AC7-1 from Ardisia crispa. Int J Cancer 2001, 93:736-740.
• [13]Roslida AH, Kim KH: Anti-inflammatory effect and anti-hyperalgesic effect of Ardisia crispa Thunb D. C. Pharmacogn Mag 2008, 4:262-268.
• [14]Hamsin DE, Hamid RA, Yazan LS, Taib CN, Ting YL: The hexane fraction of Ardisia crispa Thunb A.DC. root inhibits inflammation-induced angiogenesis. BMC Complement Altern Med 2013, 13:5. BioMed Central Full Text
• [15]Jansakul C, Baumann H, Kenne L, Samuelsson G: Ardisiacrispin a and B, Two utero-contracting saponins from ardisia crispa. Planta Med 1987, 53:45-49.
• [16]Roslida AH: Anti-Inflammatory And Analgesic Effects Of Ac-2 Isolated From Ardisia Crispa Are Mediated Via Cox-2 Inhibition. In Phd Thesis. Universiti Malaya, Kuala Lumpur, Malaysia: Physiology Department; 2004.
• [17]McCarty M, Baker C, Bucana C, Fidler I: Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002, 21:5-102002.
• [18]Abourashed EA, El-Feraly S, Hufford CD: Carboxylic acid microbial metabolites of the natural benzoquinone, Maesanin. J Nat Prod 1999, 62:714-716.
• [19]Mathur R, Gupta SK, Singh N, Mathur S, Kochupillai V, Velpandian T: Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J Ethnopharmacol 2006, 105:336-341.
• [20]Yang LK, Khoo-Beattie C, Goh KL, Chng BL, Yoganathan K, Lai YH, Butler MS: Ardisiaquinones from Ardisia teysmanniana. Phytochemistry 2001, 58:1235-1238.
• [21]Azhar-Ul-Haq , Malik A, Anis I, Khan SB, Ahmed E, Ahmed Z, Nawaz SA, Choudhary MI: Enzyme inhibiting lignans from Vitex negundo. Chem Pharm Bull 2004, 52(11):1269-1272.
• [22]Akula US, Odhav B: In vitro 5-lipoxygenase inhibition of polyphenolic antioxidants from undomesticated plants of South Africa. J Med Plant Res 2008, 2:207-212.
• [23]Fukuyama Y, Kiriyama Y, Kodama M, Iwaki H, Hosozawa S, Aki S: Total synthesis of Ardisiaquinone A, a potent 5-lipoxygenase inhibitor, isolated from Ardisia sieboldii, and degree of 5-lipoxygenase activity of its derivatives. Chem Pharm Bull 1993, 43:2211-2213.
• [24]Jackson JR, Seed M, Kircher C, Willoughby DA, Winkler JD: The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11:457-465.
• [25]Zhang J, Sun Y, Zhang JQ, Ramires FJ, Weber KT: Appearance and regression of rat air pouch tissue. J Mol Cell Cardiol 1999, 31:1005-1013.
• [26]Pakhneshan P, Birsner AE, Adini I, Becker CM, D’Amato RJ: Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci 2008, 49:3909-3913.
• [27]Ribatti D: Chicken chorioallantoic membrane angiogenesis model. Methods Mol Biol 2012, 843:47-57.
• [28]Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13(1):9-22.
• [29]Alitonou GA, Avlessi F, Sohounhloues DK, Agnaniet H, Bessiere JM, Menut C: Investigations on the essential oil of Cymbopogon giganteus from Benin for its potential use as an anti-inflammatory agent. Intl J Aromatherapy 2006, 16:37-41.
• [30]Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306-1311.
• [31]Awtry EH, Loscalzo J: Cardiovascular drugs: aspirin. Circulation 2000, 101:1206-1218.
• [32]Ammon HPT, Safayhi H, Mack T, Sabieraj J: Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 1993, 38:105-112.
• [33]Fukuyama Y, Kiriyama Y, Okino J, Kodama M, Iwaki H, Hosozawa S: Naturally occurring 5-lipoxygenase inhibitor. II. Structures and syntheses of ardisianones A and B, and maesanin, alkenyl-1,4- benzoquinones from the rhizome of Ardisia japonica. Chem Pharm Bull 1993, 41:561-565.
• [34]Fukuishi N, Takada T, Fukuyama Y, Akagi M: Antiallergic effect of Ardisiaquinone A; a potent 5-lipoxygenase inhibitor. Phytomedicine 2001, 8(6):460-464.
• [35]Hua H, Feng L, Zhang XP, Zhang LF, Jin J: Anti-angiogenic activity of julibiroside J8, a natural product isolated from Albizia julibrissin. Phytomedicine 2009, 16:703-711.